SCIRENT is excited to participate at the TCT Conference 2023 in San Francisco
SCIRENT is excited to participate at the TCT Conference from October 23-26, 2023, in San Francisco. The Transcatheter Cardiovascular Therapeutics (TCT) conference, hosted by the Cardiovascular Research Foundation (CRF), is the world’s premier educational forum for interventional cardiovascular medicine. For over 30 years, TCT has been a beacon of innovation, education, and collaboration in the […]
First patient enrolled in feasibility trial for JuxtaFlow® Renal Assist Device (RAD)
Roswell, Georgia – 9 October, 2023 – Roivios Ltd., a medical device company pioneering a revolutionary treatment to reduce poor surgical outcomes associated with Acute Kidney Injury(AKI), today announces the first patient has been enrolled in the BIPASS-AKI early feasibilitystudy for the JuxtaFlow Renal Assist Device (RAD). Insertion of the proprietary JuxtaFlowcatheters was overseen by […]
Join SCIRENT at ESC Congress 2023
SCIRENT will be participating in the renowned ESC Congress in Amsterdam from 25th to 28th August 2023. This prestigious event is a powerful platform for us as it brings together leading experts from the field of cardiology to shape the future of this field. ESC Congress is the place where cardiologists and researchers of all […]
Join Us in Prague for the ESC Heart Failure Meeting
Save the dates in your agenda and join us in Prague from 20 to 23 May 2023 for the ESC Heart Failure Association (HFA) annual meeting bringing together scientists, healthcare professionals, and other players from around the world. The world’s leading event covers the entire spectrum of heart failure, from prevention to diagnosis and treatment. Meet […]
Conferences in Cardiovascular Clinical Research 2023
SCIRENT is thrilled to announce that we will be attending several high-ranking cardiovascular conferences in 2023. Meet our team to discover how SCIRENT, a specialized cardiovascular research organization, can help your business develop innovative therapies. Our competence in clinical research covers the whole range of a clinical trials, from early protocol development to regulatory consulting […]
Meet Us at ESC Congress 2022 in Barcelona
SCIRENT is excited to participate at the ESC Congress 2022 in Barcelona, which is taking place from 26-29 August 2022. Please book an appointment with our leadership to learn more about our industry-leading cardiovascular research services and patient recruitment capabilities. SCIRENT is a specialty CRO focused on cardiovascular research. We offer an excellent network of […]
Meet Us at AHA 2021
10.11.2021. SCIRENT is attending the American Heart Association’s Scientific Sessions, AHA 2021, from November 13-15, 2021 as a proud exhibitor. Visit our booth and connect with us live to learn more about our industry-leading cardiovascular research services, patient recruitment capabilities, and study experience. The American Heart Association’s Scientific Sessions 2021 is the largest cardiovascular meeting […]
SCIRENT Appoints Dr. Maximilian Posch, MD, as Chief Medical Officer
BERLIN, Sept. 21, 2021 /PRNewswire/ SCIRENT, an international full-service cardiovascular contract research organization (CRO), is proud to appoint Dr. Maximilian Posch as Chief Medical Officer. In his new position, Dr. Posch will be an important driver of SCIRENT’s growth by contributing medical and scientific expertise to support SCIRENT’s service portfolio and consulting clients on early-phase […]
Innovative Medical Device for Heart Failure Treatment Delivers Promising Results
Berlin Heals’ innovative implantable C-MIC device delivers encouraging clinical results in the treatment of heart failure.
Restarting by Design: Agile Crisis Management for Rapid Resumption of Cardiovascular Clinical Trials
The entire landscape of hospital-based clinical trials dramatically changed when COVID-19 singlehandedly stopped the global recruitment of ongoing cardiovascular trials. Heart failure clinical trials were already subject to factors such as regional variation in clinical practice, trial implementation, and patient characteristics, which drive event rate and treatment effect size assumptions key to demonstrating clinical benefit. […]
